CORRESP Filing
Artiva Biotherapeutics, Inc.
Date: Aug. 13, 2025 · CIK: 0001817241 · Accession: 0001193125-25-180011
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289325
Letter
Re: Artiva Biotherapeutics, Inc. Registration Statement on Form S-3 (File No. 333-289325) Filed: August 6, 2025 Request for Acceleration of Effective Date Dear Mr. Buchmiller, In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “ Registrant ”) hereby requests that the Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-289325) (the “ Registration Statement ”) to become effective on August 15, 2025, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as the Registrant or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Registrant hereby authorizes each of Carlos Ramirez and Christine S. Kim of Cooley LLP to make such a request on its behalf. Once the Registration Statement has been declared effective, please confirm that event with Carlos Ramirez of Cooley LLP at (858) 550-6157 or cramirez@cooley.com, or in his absence, Christine S. Kim at (858) 550-6110 or cskim@cooley.com.
A RTIVA B IOTHERAPEUTICS , I NC . 5505 Morehouse Drive, Suite 100 San Diego CA 92121 August 13, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller
Very truly yours,
Artiva Biotherapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP A RTIVA B IOTHERAPEUTICS , I NC . 5505 Morehouse Drive, Suite 100 San Diego CA 92121 August 13, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller Re: Artiva Biotherapeutics, Inc. Registration Statement on Form S-3 (File No. 333-289325) Filed: August 6, 2025 Request for Acceleration of Effective Date Dear Mr. Buchmiller, In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “ Registrant ”) hereby requests that the Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-289325) (the “ Registration Statement ”) to become effective on August 15, 2025, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as the Registrant or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Registrant hereby authorizes each of Carlos Ramirez and Christine S. Kim of Cooley LLP to make such a request on its behalf. Once the Registration Statement has been declared effective, please confirm that event with Carlos Ramirez of Cooley LLP at (858) 550-6157 or cramirez@cooley.com, or in his absence, Christine S. Kim at (858) 550-6110 or cskim@cooley.com. Very truly yours, Artiva Biotherapeutics, Inc. By: /s/ Fred Aslan, M.D. Fred Aslan, M.D. President and Chief Executive Officer cc: Neha Krishnamohan, Artiva Biotherapeutics, Inc. Jennifer Bush, Artiva Biotherapeutics, Inc. Andrew Cronauer, Artiva Biotherapeutics, Inc. Carlos Ramirez, Cooley LLP Christine S. Kim, Cooley LLP